COVID-19 We need yachts to support cancer patients during the outbreak.

COVID-19 We need yachts to support cancer patients during the outbreak.

COVID-19 We need yachts to support cancer patients during the outbreak. COVID-19 We need yachts to support cancer patients during the outbreak. COVID-19 We need yachts to support cancer patients during the outbreak.

Yachts for Cancer during the COVID-19 Pandemic


We are looking for yachts to serve as medical clinics for high-risk patients needing treatments in a safe and virus-free environment away from the hospital.  

Yachts may be donated for tax deductions or loaned for use until the pandemic is over.  

We will pay the carrying costs while the vessel is on loan.

In a market where yacht sales are significantly reduced, support for this critically important cause is an excellent solution.

About Us


The Foundation

Yacht Donation Program

The Foundation

The Foundation is committed to reducing the suffering from cancer through advances in early detection technology and global education on cancer prevention and detection. 


Our Mission

Yacht Donation Program

The Foundation

We leverage the value of donations from multiple types and sources to support clinical trials for new technology and public awareness campaigns on the importance of cancer screening.


Yacht Donation Program

Yacht Donation Program

Yacht Donation Program

We increase the value of yacht sales by providing owners with several options to combine revenue with tax deductions and broad recognition for their philanthropic generosity.

Contact Us

Come aboard our voyage to stop Cancer before it stops us.

Help Our Cause

Your support and contributions will enable us to undertake 

clinical trials for cancer early detection solutions. 

Your generous donation will fund our mission to end suffering for millions of people around the world.

Pay with PayPal or a debit/credit card


Canary Center at Stanford for Cancer Early Detection

“The greatest advances in cancer research will be obtained — and more lives saved — by focusing translational research on early detection.”

MRC Cancer Cell Unit University of Cambridge

"Earlier diagnosis is the most promising approach to improve long-term survival of patients with cancer."         Professor Rebecca Fitzgerald

Cancer Research UK

"The early detection and interception of cancer will be one of the main ways in which we will beat the disease in the future. Not only does it provide routes to more effective treatment, it also provides health systems around the world a way in which to grapple with the mounting costs of care in complex diseases such as cancer."             

                       Dr Iain Foulkes, Executive Director Research & Innovation, CRUK

Oregon Health & Science University, Knight Cancer Institute

The new knowledge that has revolutionized treatment, has done little to help catch cancer early and ideally, prevent it.

Even as treatment options have dramatically improved, with once-a-day pills that target the specific biology of each patient’s disease, early detection of cancer has been frozen in time. Today, we still use the same screening tools that we’ve deployed for decades. Mammograms and PSA tests for prostate cancer are the best we have today, but they’re woefully inadequate. They miss some cancers while triggering many unnecessary biopsies and treatments.

We know cancer is an easier foe when caught early. It is cheaper to treat. And patients live longer and suffer less when it is detected early. Indeed, targeted therapy and early detection will prove to be inextricably linked. Early stage cancers are easier to treat because they harbor fewer mutations and molecular defects. 

Cancer Research UK

Earlier diagnosis of cancer offers the greatest potential for transformational improvements in patient outcomes.

The chances of survival are increased significantly for almost all patient groups if the disease can be diagnosed and treated at an early stage. For example, a patient diagnosed with stage 1 lung cancer has over 70% chance of survival beyond one year. This drops to less than 15% if diagnosed at stage 4.